By Richard B. Silverman,Mark W. Holladay
The natural Chemistry of Drug layout and Drug motion, 3rd Edition, represents a distinct method of medicinal chemistry according to actual natural chemical ideas and response mechanisms that rationalize drug motion, which permits reader to extrapolate these center ideas and mechanisms to many similar sessions of drug molecules.
This re-creation contains updates to all chapters, together with new examples and references. It displays major adjustments within the means of drug layout over the past decade and preserves the winning technique of the former variations whereas together with major alterations in structure and coverage.
This textual content is designed for undergraduate and graduate scholars in chemistry learning medicinal chemistry or pharmaceutical chemistry; study chemists and biochemists operating in pharmaceutical and biotechnology industries.
- Updates to all chapters, together with new examples and references
- Chapter 1 (Introduction): thoroughly rewritten and elevated as an summary of subject matters mentioned intimately during the book
- Chapter 2 (Lead Discovery and Lead Modification): Sections on assets of compounds for screening together with library collections, digital screening, and computational equipment, in addition to hit-to-lead and scaffold hopping; increased sections on assets of lead compounds, fragment-based lead discovery, and molecular photographs; and deemphasized solid-phase synthesis and combinatorial chemistry
- Chapter three (Receptors): Drug-receptor interactions, cation-π and halogen bonding; atropisomers; case historical past of the insomnia drug suvorexant
- Chapter four (Enzymes): extended sections on enzyme catalysis in drug discovery and enzyme synthesis
- Chapter five (Enzyme Inhibition and Inactivation): New case histories:
- for aggressive inhibition, the epidermal development issue receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib
- for transition kingdom analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, in addition to the mechanism of the multisubstrate analog inhibitor isoniazid
- for sluggish, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin
- Chapter 7 (Drug Resistance and Drug Synergism): This new bankruptcy contains subject matters taken from chapters within the prior version, with many new examples
- Chapter eight (Drug Metabolism): Discussions of toxicophores and reactive metabolites
- Chapter nine (Prodrugs and Drug supply Systems): dialogue of antibody–drug conjugates